Zydus Lifesciences Arm Gets Usfda Tentative Approval To Market Hypertension Drug

Zydus Lifesciences Arm Gets Usfda Tentative Approval To Market Hypertension Drug

By, Admin 9 May 2022

Zydus Lifesciences On Friday Said Its Subsidiary Zydus Worldwide Dmcc Has Received Tentative Approval From The Us Health Regulator To Market Its Generic Version Of Selexipag Tablets, Used To Treat Pulmonary Arterial Hypertension In Adults. Zydus Lifesciences On Friday Said Its Subsidiary Zydus Worldwide Dmcc Has Received Tentative Approval From The Us Health Regulator To Market Its Generic Version Of Selexipag Tablets, Used To Treat Pulmonary Arterial Hypertension In Adults. The Approval By The Us Food And Drug Administration (Usfda) Is For Selexipag Tablets In The Strengths Of 200 Mcg, 400 Mcg, 600 Mcg, 800 Mcg, 1,000 Mcg, 1,200 Mcg, 1,400 Mcg, And 1,600 Mcg, The Company Said In A Regulatory Filing. These Are The Generic Equivalent Of The Reference Listed Drug Uptravi. It Will Be Manufactured At The Group'S Formulation Facility At Sez, Ahmedabad, The Company Said. Selexipag Is Used In Adults To Treat Pulmonary Arterial Hypertension (Pah) To Delay Disease Progression And Reduce The Risk Of Hospitalisation For Pah. Citing Iqvia Mat March 2022 Data, The Company Said Uptravi Tablets Had Annual Sales Of Usd 551 Million In The Us. The Group Now Has 331 Approvals And Has So Far Filed Over 400 Abbreviated New Drug Applications Since The Commencement Of The Filing Process In Fy2003-04, Zydus Said. Pti Rkl Bal Bal

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!